Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000875
English
Authors' recommendations:
Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension is recommended as an option for use within NHS Wales for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/mercaptopurine%20%28Xaluprine%29%20FAR.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Administration, Oral
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.